$8.6 Billion Viral Vectors and Plasmid DNA Manufacturing

17 Jun 2021
www.globenewswire.com
Gene TherapyCell TherapyVaccineAcquisitionCollaborate
Dublin, June 17, 2021 (GLOBE NEWSWIRE) -- The "Viral Vectors and Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report by Vector Type (AAV, Lentivirus), by Workflow, by Application, by End Use, by Disease, by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering. The global viral vectors and plasmid DNA manufacturing market size is expected to reach USD 8.6 billion by 2028 The market is expected to expand at a CAGR of 18.8% from 2021 to 2028. The robust pipeline for gene therapies and viral-vector-based vaccines has primarily driven the market.Amidst the COVID-19 pandemic, the demand for viral vectors has rapidly increased especially in vaccinology. This led to expanding manufacturing capabilities by operating players to meet the growing demand. The application of these vectors in vaccine development has witnessed significant growth in 2020.Also, an increase in the number of gene therapy-based discovery programs initiated by biotechnology and pharmaceutical companies is expected to drive the demand for scalable production of gene therapy vectors. Owing to this, several private and public agencies are providing funds to accelerate advancements in the manufacturing processes for viral vectors.Besides, the implementation of single-use technology can lead to significant savings in capital, operating costs, materials, and labor. The use of this equipment will enhance efficiency and improve flexibility, leading to high yields of the final product. Thus, advancements in single-use technology directly impact revenue growth in this space.Viral Vectors And Plasmid DNA Manufacturing Market Report Highlights Key Topics Covered: Chapter 1 Executive SummaryChapter 2 Research MethodologyChapter 3 Market Variables, Trends, & Scope3.1 Market Segmentation & Scope3.2 Market Dynamics3.2.1 Market drivers analysis3.2.1.1 Robust pipeline for gene therapies and viral vector vaccines3.2.1.2 Technological advancements in manufacturing vectors3.2.1.3 Highly competitive market and various strategies undertaken by market entities3.2.2 Market restraint analysis3.2.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy and viral vectors3.2.3 Market challenge analysis3.2.3.1 Production capacity challenges3.2.3.2 Manufacturing challenges pertaining to large scale production of vectors3.2.4 Market opportunity Analysis3.2.4.1 Facility expansion for cell and gene therapies3.3 COVID-19 Impact Analysis3.4 Viral Vector Production: Stepwise Challenges & Solutions3.4.1 Host cell production & banking Needs3.4.2 Viral vector production, Fill & Finish: challenges & solutions3.4.3 Viral vector production, analytics: challenges & solutions3.5 Penetration & Growth Prospect Mapping for Vector Type, 20203.6 Industry Analysis - Porter's3.7 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)3.8 Penetration & Growth Prospect Mapping for Prominent Industry Players, 20203.9 Manufacturer's Landscape3.10 Viral Vector Production Capacity Mapping Analysis3.10.1 North America: capacity & service mapping3.10.2 Europe: capacity & service mapping3.10.2.1 Cobra Biologics (Sweden and the U.K.)3.10.2.2 Biovian (Finland)3.10.2.3 Oxford Biomedica (U.K.)3.10.2.4 Lonza Pharma & Biotech (The Netherlands)3.10.2.5 FinVector Oy (Finland)3.10.2.6 Fujifilm Diosynth Biotechnologies (Denmark)3.10.2.7 Fujifilm Diosynth Biotechnologies (U.K.)3.10.2.8 Catalent Inc. (Belgium)3.10.2.9 Novasep (Belgium)3.10.2.10 Exothera (Belgium)3.10.2.11 Delphi Genetics SA (Belgium)3.10.2.12 Yposkesi (France)3.10.2.13 VIVEbiotech (Spain)3.10.2.14 MolMed SpA (Italy)3.10.2.15 Anemocyte (Italy)3.11 List of Companies with Portfolio Comprising Vector-based Therapeutic Candidates3.12 List of Vector ManufacturersChapter 4 Viral Vector Production: Costs4.1 Cost Models for Viral Vector Production4.1.1 Campaign model4.1.2 Day rate model4.1.3 Hybrid model4.2 Viral Vector Manufacturing Pricing Analysis4.2.1 Parameters affecting price4.2.2 AAV: Pricing analysis4.2.3 Lentivirus: Pricing analysis4.2.4 Adenovirus: Pricing analysis4.2.5 Retrovirus: Pricing analysis4.2.6 Plasmid: Pricing analysis4.2.7 Gene Synthesis Cost4.2.8 Genes/ Gene Fragment Cost AnalysisChapter 5 Viral Vector Production & Yield Analysis5.1 Production Yields: Biomarin, Spark Therapeutics & Solid Biosciences5.2 Various Modes of Vector Production to increase & achieve Target Doses5.2.1 Adenoviral vectors5.2.2 Gamma- retroviral (MLV - murineleukemia virus) vectors5.2.3 Lentiviral vectors5.2.4 AAV vectors5.2.5 rAAV vectors5.2.5.1 rAAV Production: challenges & solutions5.3 Total vector quantity produced per day and yield volume using different cell culture systems5.4 Measures undertaken to optimize manufacturing of viral vectors for cell and gene therapy5.5 Analysis of large- and small-scale production of viral vectors based on batch size5.5.1 Small-scale/laboratory-scale cell culture systems5.5.2 Large-scale cell culture systems5.6 Common Practices for Small-Scale (10-50L) Adenovirus Vector ManufacturingChapter 6 Viral Vector Manufacturing: Process Economic Considerations & Challenges6.1. Technological Advances in Manufacturing6.1.1. Stable producer cell lines6.1.2 Transient production6.1.3 Lentiviral vector production process6.1.3.1 Developments in LentiVector platform6.2 CoGs Analysis of the Baseline Process6.2.1 Raw material6.2.2 Labor costs6.2.3 Process costs6.3 Regulatory Expectations6.4 Approaches for Viral Vector Supply Gene Therapy6.4.1 Gene therapy manufacturing facilities: trends & types6.4.2 Gene therapy road map: key external trendsChapter 7 Viral Vector Manufacturing Market: Strategic Alliances7.1 Is The Time Right To Invest In Gene Therapy Sector?7.2 Strategic Approaches for Market Scale-Up7.2.1 Partnership models7.2.2 Acquisition7.2.3 Minority interest (ownership)7.2.4 Joint venture7.2.5 Alliance7.2.6 Franchise7.3 Collaborations in Viral Vector Manufacturing Market7.3.1 Breakthrough growth: Lonza, Oxford Biomedica & othersChapter 8 Vector Type Business Analysis8.1 Market: Vector Type Movement Analysis8.2 Adenovirus8.3 Retrovirus8.4 Adeno-associated Virus (AAV)8.5 Lentivirus8.6 Plasmid DNA8.7 OthersChapter 9 Workflow Business Analysis9.1 Market: Workflow Movement Analysis9.2 Upstream Processing9.2.1 Market estimates and forecast, 2017 - 2028 (USD Million)9.2.2 Vector amplification and expansion9.2.3 Vector recovery/harvesting9.3 Downstream Processing9.3.1 Market estimates and forecast, for 2017 - 2028 (USD Million)9.3.2 Purification9.3.3 Fill finishChapter 10 Application Business Analysis10.1 Market: Application Movement Analysis10.2 Antisense & RNAi Therapy10.2.1 Market for antisense, & RNAi therapy, 2017 - 2028 (USD Million)10.3 Gene Therapy10.4 Cell Therapy10.5 Vaccinology10.6 Research ApplicationsChapter 11 End-use Business Analysis11.1 Market: End-use Movement Analysis11.2 Pharmaceutical and Biopharmaceutical Companies11.3 Research InstitutesChapter 12 Disease Business Analysis12.1 Market: Disease Movement Analysis12.2 Cancer12.3 Genetic Disorders12.4 Infectious Diseases Companies Mentioned For more information about this report visit
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.